News and Trends 14 Dec 2022 PrecisionLife to work on R&D with Ono Pharmaceutical …and patient stratification biomarkers in central nervous system (CNS) disorders for development by Ono. PrecisionLife analyzes multi-modal datasets including genomic, clinical, and epidemiological data to stratify patients and understand subgroup-relevant… December 14, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 May 2023 Schizophrenia injection gets FDA approval …evaluating UZEDY in patients with schizophrenia: TV46000-CNS-30072 (the RISE study), and TV46000-CNS-30078 (the SHINE study). “The approval of the first product formulated with our technology is a pivotal moment for… May 2, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 30 Jul 2025 Targeting orexin: the future of narcolepsy treatments …is made of sodium oxybate, a central nervous system (CNS) depressant. A CNS depressant, colloquially known as a ‘downer,’ is meant to slow down brain activity. London-based Hikma Pharmaceuticals has… July 30, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 24 Apr 2025 21 UK biotech companies you should know about …are currently for undisclosed central nervous system (CNS) indications. Back in 2020, Evox Therapeutics signed a major deal with Eli Lilly, worth up to $1.1 billion. The research collaboration and… April 24, 2025 - 27 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 29 Oct 2025 Parkinson’s disease: biotech’s pursuit for more therapies …the clinic was forged between Belgian central nervous system (CNS) disease therapeutics company Clouds of Care and Swiss research company Indivi. Set on advancing precision medicine, the two will combine neuro-electrophysiology with digital health technology… October 29, 2025 - 12 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 19 Sep 2023 Five biotech companies taking Los Angeles by storm …with $140 million, Capsida began with a focus on central nervous system (CNS) disorders, and has since expanded into serious eye diseases through its partnership with AbbVie. The Los Angeles… September 19, 2023 - 6 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 12 May 2017 UPDATE: Italian Pharma receives €11M for Parkinson’s Drug Approval …an Italian biotech focused on CNS diseases, is on a roll. The latest win? FDA approval of its Parkinson’s drug, Xadago. Just in time for World Parkinson’s Day on April… May 12, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2022 Watch: IRLAB CEO Richard Godfrey IRLAB discovers and develops novel treatments of Parkinson’s disease and other CNS disorders. The company’s most advanced drug candidates, mesdopetam (IRL790) and pirepemat (IRL752), are in phase IIb and are… December 20, 2022 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 8 Mar 2023 5 women leading the way in biotech …for the treatment of central nervous system (CNS) disorders including therapies for schizophrenia and Parkinson’s disease. She believes that there is plenty of scope in polypharmacology, which is the use… March 8, 2023 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2016 Stories We Didn’t Cover: Next Human CRISPR Trials by Intellia? …Novartis announced it’s looking to get rid of its CNS portfolio, which is also based on small molecules. TxCell has made a deal with Inserm Transfert for its CD8+ Tregs…. December 9, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Interview 31 Oct 2018 Biotech Investment Strategies: How, When and Where to Invest …CNS — those are the indication areas that will provide the majority of biotech opportunities. But ultimately we are looking at each investment by itself. Sometimes we invest in things… October 31, 2018 - 6 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 10 Sep 2025 Kriya Therapeutics has raised over $1.2 billion, but for what? …when administered as an injection by penetrating the central nervous system (CNS) to reduce the severity and number of pain attacks. While early preclinical data on its geographical atrophy therapy… September 10, 2025 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email